#Sweden #Stockholm #revenue growth #Biopharma #Sobi

Swedish Orphan Biovitrum AB's Q2 2026 Report: A Comprehensive Overview

Swedish Orphan Biovitrum AB (Sobi®) has unveiled its financial results for the second quarter of 2026, showcasing remarkable growth and strategic pipeline progress that highlights the company’s commitment to addressing rare diseases. With total revenue showing a substantial increase, Sobi continues to solidify its position in the biopharmaceutical sector.

Strong Revenue Performance

In Q2 2026, Sobi reported a total revenue increase of 29% at constant exchange rates (CER) and 27% at actual rates, amounting to SEK 7,842 million, up from SEK 6,175 million in the same quarter last year. This impressive growth is driven primarily by the company's strong performance in the haematology and immunology sectors.

Haematology and Immunology Growth

Revenue from haematology climbed to SEK 5,726 million, marking a 27% increase at CER. This uptick was largely attributed to robust sales of key products such as Altuvoct, which generated SEK 1,554 million, and Doptelet, which achieved SEK 1,628 million in sales.

In the immunology segment, revenue surged 37% at CER, reaching SEK 1,711 million. The success of Gamifant and Kineret played a pivotal role, with sales figures of SEK 794 million and SEK 861 million, respectively.

Additionally, Sobi's strategic portfolio saw an outstanding 53% growth at CER, leading to revenues of SEK 5,095 million, underscoring the efficacy of its focused business strategy.

Earnings and Financial Metrics

The company’s financial health is reflected in its adjusted EBITA margin, which rose to 35%, an increase from the previous 34%. The EBITA totaled SEK 2,843 million, corresponding to a 36% margin, up from 30% a year earlier. Notably, the earnings per share also improved significantly, with basic EPS before dilution at SEK 3.17, up from SEK 1.85, and diluted EPS at SEK 3.14, compared to SEK 1.83 in the prior year.

Operating cash flow stood at SEK 1,912 million, up from SEK 1,448 million, reinforcing Sobi’s operational efficiency and ability to generate cash from its activities.

Pipeline Updates and Future Outlook

Sobi received a Complete Response Letter (CRL) regarding a manufacturing issue for a product aimed at treating uncontrolled gout, but the company is optimistic about its resubmission path. Moreover, significant progress was made in the Phase 3 REDUCE 2 study of Pozdeutinurad, which reported positive topline results in the treatment of gout, marking a promising step forward.

Looking ahead, Sobi has updated its revenue growth forecasts for 2026, predicting mid-to-high teens percentage growth at CER, revising the previous estimate of low double-digit growth. The adjusted EBITA margin is expected to remain in the mid-to-high 30s percentage range of revenue, further enhancing investor confidence.

Conclusion

As Sobi continues to innovate and expand its product offerings, the second quarter report for 2026 indicates a strong trajectory towards sustainable growth and impactful advancements in the treatment of rare diseases. The upcoming conference call on July 16, 2026, will allow investors and analysts to engage with Sobi’s leadership for insights into these promising developments.

In summary, Sobi is not only demonstrating solid financial performance but also making significant strides in research and development, positioning itself as a leader in the biopharmaceutical industry.